Following the first approval of biosimilars in the US, FDA has received even more applications and the industry is expecting 2 more products receiving the green light this year. Nonetheless, the recent Remicade case between Celltrion and JandJ has also casted doubts amongst market participants.
The 3rd annual Biosimilars USA conference will return in November to discuss the following topics in such evolving market landscape:
Examine the latest biosimilar applications and cases
Evaluate the global biosimilars market and assist delegates to define the optimal penetration strategy
Reveal latest regulatory and legal updates to ensure smooth approval and licensing process
Debate how to de-risk and develop a holistic value chain for biosimilars commercialization
Define post-launch and marketing plan: What are the distribution channels?
Portfolio and branding strategy of biosimilars: How should we build a sustainable business model?
Assess technological breakthroughs to speed up characterization and drug development programs
Understand rationale behind pricing and discount - engage with your payers
Chairman:
Richard Dicicco, Chairman, Harvest Moon Pharmaceuticals USA, Inc.
Elite Speaker Panel 2016:
Edric Engert, Senior Vice President, Biosimilars, Teva Pharmaceuticals
Gustavo Grampp, Ph.D., Director RandD Policy - Biosimilars, Amgen Inc.
Hillel Cohen, Executive Director, Scientifi c Affairs, Sandoz
Andrew Simpson, Scientifi c Director, Orygen Biotechnologia S/A
Dr. Jianguo Yang, CEO, Abpro-China; Vice President, Abpro-US
Daniel Alvarez, Senior Director, Asset Lead, Global Established Pharma, Pfi zer Inc.
PLUS TWO INTERACTIVE HALF-DAY PRE-CONFERENCE WORKSHOPS
A: Leveraging Successful Patient Recruitment
and Retention Strategies in Biosimilars Research (UBC - An Express Scripts Company)
B: Biosimilars: Considerations for
Optimizing Access and Price (MKTX Market Access Solutions, LLC)
The 3rd annual Biosimilars USA conference will return in November to discuss the following topics in such evolving market landscape:
Examine the latest biosimilar applications and cases
Evaluate the global biosimilars market and assist delegates to define the optimal penetration strategy
Reveal latest regulatory and legal updates to ensure smooth approval and licensing process
Debate how to de-risk and develop a holistic value chain for biosimilars commercialization
Define post-launch and marketing plan: What are the distribution channels?
Portfolio and branding strategy of biosimilars: How should we build a sustainable business model?
Assess technological breakthroughs to speed up characterization and drug development programs
Understand rationale behind pricing and discount - engage with your payers
Chairman:
Richard Dicicco, Chairman, Harvest Moon Pharmaceuticals USA, Inc.
Elite Speaker Panel 2016:
Edric Engert, Senior Vice President, Biosimilars, Teva Pharmaceuticals
Gustavo Grampp, Ph.D., Director RandD Policy - Biosimilars, Amgen Inc.
Hillel Cohen, Executive Director, Scientifi c Affairs, Sandoz
Andrew Simpson, Scientifi c Director, Orygen Biotechnologia S/A
Dr. Jianguo Yang, CEO, Abpro-China; Vice President, Abpro-US
Daniel Alvarez, Senior Director, Asset Lead, Global Established Pharma, Pfi zer Inc.
PLUS TWO INTERACTIVE HALF-DAY PRE-CONFERENCE WORKSHOPS
A: Leveraging Successful Patient Recruitment
and Retention Strategies in Biosimilars Research (UBC - An Express Scripts Company)
B: Biosimilars: Considerations for
Optimizing Access and Price (MKTX Market Access Solutions, LLC)
